Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.
The distinction of rhabdomyosarcoma (RMS) from other small blue round cell tumors of childhood, such as Ewing's sarcoma/peripheral primitive neuroectodermal tumor (pPNET) and neuroblastoma, continues to present a diagnostic challenge to pathologists. The recent recognition of the master role of myogenic regulatory proteins in skeletal muscle commitment and differentiation, and the availability of monoclonal antibodies to two of them (myogenin and MyoD1), has prompted us to test their diagnostic utility in routinely processed, formalin-fixed, and deparaffinized tissue. Preliminary studies had demonstrated that, with the use of heat-induced epitope retrieval techniques, expression of myogenin and MyoD1 could be documented specifically in nuclei of fetal skeletal muscle by the respective antibodies. We performed a retrospective immunohistochemical analysis on 72 cases of small blue round cell tumors, including 33 RMSs, 1 metastatic myogenous Wilms' tumor, 26 Ewing's sarcomas/pPNETs, and 12 neuroblastomas. Nuclear expression of myogenin and MyoD1 were both found in 30/33 non-overlapping cases of RMS, with no significant differences in the sensitivity with respect to histological subtypes, and in 1/1 case of myogenous Wilms' tumor. None of the neuroblastomas or Ewing's sarcomas/pPNETs demonstrated positive nuclear staining with either antibody. However, most of the neuroblastomas, and occasional Ewing's sarcomas/pPNETs, showed variable fibrillary, cytoplasmic immunoreactivity with antibody to MyoD1. We conclude that, with the use of microwave-based epitope retrieval, antibodies to myogenin and MyoD1 are both useful markers for the identification of RMS among other small blue round cell tumors of childhood, but antibodies to myogenin have technical advantages over those to MyoD1, as the latter may cross-react with an unknown cytoplasmic antigen in non-muscle cells and tumors.
D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D006801:Humans; D007150:Immunohistochemistry; D017570:MyoD Protein / Q000032:analysis* / Q000276:immunology; D018008:Myogenin / Q000032:analysis* / Q000276:immunology; D018302:Neoplasms, Neuroepithelial / Q000737:chemistry / Q000175:diagnosis; D009447:Neuroblastoma / Q000737:chemistry / Q000175:diagnosis; D018241:Neuroectodermal Tumors, Primitive, Peripheral / Q000737:chemistry / Q000175:diagnosis; D012208:Rhabdomyosarcoma / Q000737:chemistry / Q000145:classification* / Q000175:diagnosis*; D012512:Sarcoma, Ewing / Q000737:chemistry / Q000175:diagnosis; D015534:Trans-Activators / Q000032:analysis* / Q000276:immunology
C503799:MYOG protein, human; D017570:MyoD Protein; C057363:MyoD1 myogenic differentiation protein; D018008:Myogenin; D015534:Trans-Activators